Actos, a popular diabetes drug, has been linked to an increased risk of bladder cancer. If you or someone you care about has been taking this medication and has been diagnosed with bladder cancer, you should speak with our team at Sullivan & Brill, LLP. We are knowledgeable about this drug and the lawsuits that have been filed against the manufacturer. The consultation is free and if your case is accepted, you will not be required to pay any fees or expenses unless a recovery is obtained on your behalf.
Actos, generically known as pioglitazone hydrochloride, is used to treat Type II diabetes. It is manufactured by Takedia Pharmaceuticals, Inc. and was put on the market in July of 1999. On September 17, 2010, the Federal Drug Administration (FDA) issued a safety warning, advising the public that it was reviewing data from an ongoing study of the association between Actos and an increased risk of bladder cancer and that the findings indicate that further study is needed.
In June of 2011, Actos was pulled from the French market after a study commissioned by the French government confirmed that it was associated with an increased risk of bladder cancer. In response thereto, in August of 2011, the FDA ordered Takedia to change the label on Actos to advise the public of the increased risk of bladder cancer associated with the drug. Lawsuits have been filed against Takedia Pharmaceuticals alleging that it knew of this increased risk of bladder cancer, yet it failed to warn the public, and in fact, affirmatively withheld the fact that some individuals in a 2005 study of Actos were diagnosed with bladder cancer.
Contact our firm to discuss your case and learn more about the side effects of Actos.
Copyright © Sullivan Brill Personal Injury Attorneys
